Page 2253 - Hematology_ Basic Principles and Practice ( PDFDrive )

2000 Part XII Hemostasis and Thrombosis

Cataland SP, Wu HM: Diagnosis and management of complement mediated Loirat C, Fakhouri F, Gema A, et al: An international consensus approach
thrombotic microangiopathies. Blood Rev 28:67–74, 2014. to the management of atypical hemolytic uremic syndrome in children.
Chapin J, Shore T, Forsberg P, et al: Hematopoietic transplant-associated Ped Nephrol 31:15–39, 2016.
thrombotic microangiopathy: case report and review of diagnosis and Lotta L, Wu H, Mackie I, et al: Residual plasmatic activity of ADAMTS13
treatments. Clin Adv Hematol Oncol 12:565–573, 2014. is correlated with phenotype severity in congenital thrombotic thrombo-
Fakhouri F, Roumenina L, Provot F, et al: Pregnancy-associated hemolytic cytopenic purpura. Blood 120:440–448, 2012.
uremic syndrome revisited in the era of complement gene mutations. J McCrae KR: Thrombocytopenia in pregnancy. Hematology Am Soc Hematol
Am Soc Nephrol 21:859, 2010. Educ Program 2010:397–402, 2010.
Froissart A, Buffet M, Veyradier A, et al: Efficacy and safety of first-line Moschcowitz E: Hyaline thrombosis of the terminal arterioles and capillaries:
rituximab in severe, acquired thrombotic thrombocytopenic purpura with a hitherto undescribed disease. Proc N Y Pathol Soc 24:21–24, 1924.
a suboptimal response to plasma exchange. Experience of the French Nadasdy T: Thrombotic microangiopathy in renal allografts: the diagnostic
Thrombotic Microangiopathies Reference Center. Crit Care Med 40:104, challenge. Curr Opin Organ Transplant 19:283–292, 2014.
2012. Obrig TG, Karpman D: Shiga toxin pathogenesis: kidney complications and
Furlan M, Robles R, Solenthaler M, et al: Deficient activity of von Willebrand renal failure. Curr Top Microbiol Immunol 357:105, 2012.
factor-cleaving protease in chronic relapsing thrombotic thrombocytope- Orth D, Wurzner R: Complement in typical hemolytic uremic syndrome.
nic purpura. Blood 89:3097, 1997. Semin Thromb Hemost 36:620, 2010.
Gasser C, Gautier E, Steck A, et al: Hämolytisch-urämische Syndrome: Rock GA, Shumak KH, Buskard NA, et al: Comparison of plasma exchange
bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen with plasma infusion in the treatment of thrombotic thrombocytopenic
Anämien. Schweiz Med Wochenschr 85:905–909, 1955. purpura. N Engl J Med 325:393, 1991.
George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl Scully M, Goodship T: How I treat thrombotic thrombocytopenia purpura
J Med 371:654, 2014. and atypical haemolytic uremic syndrome. Br J Haematol 164:759, 2014.
Goel R, Ness PM, Takemoto CM, et al: Platelet transfusions in platelet con- Scully M, McDonald V, Cavenagh J, et al: A phase 2 study of the safety and
sumptive disorders are associated with arterial thrombosis and in-hospital efficacy of rituximab with plasma exchange in acute acquired thrombotic
mortality. Blood 1251470–1251476, 2015. thrombocytopenic purpura. Blood 118:1746, 2011.
Hovinga JA, Vesely SK, Terrell DR, et al: Survival and relapse in patients with Tarr PI: Shiga toxin-associated hemolytic uremic syndrome and thrombotic
thrombotic thrombocytopenic purpura. Blood 115:1500, 2010. thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney
Ibarra C, Amaral MM, Palermo MS: Advances in the pathogenesis and Int Suppl 112:S29, 2009.
therapy of hemolytic uremic syndrome caused by Shiga Toxin-2. IUBMB Tsai H-M, Lian ECY: Antibodies to von Willebrand factor-cleaving protease
Life 65:827, 2013. in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585,
Karpman D, Sartz L, Johnson S: Pathophysiology of typical hemolytic uremic 1998.
syndrome. Semin Thromb Hemost 36:575, 2010. Wada H, Matsumoto T, Yamashita Y: Natural history of thrombotic throm-
Kavanagh D, Goodship H, Richards A: Atypical hemolytic uremic syndrome. bocytopenic purpura and hemolytic uremic syndrome. Semin Thromb
Semin Nephrol 33:508, 2013. Hemost 40:866–873, 2014.
Kerr H, Richards A: Complement-mediated injury and protection of Wong CS, Jelacic S, Habeeb RL, et al: The risk of the hemolytic uremic
endothelium: lessons from atypical haemolytic uraemic syndrome. syndrome after antibiotic treatment of Escherichia coli 0157:H7 infec-
Immunobiology 217:195, 2012. tions. N Engl J Med 342:930, 2000.
Lim W, Vesely SK, George JN: The role of rituximab in the management
of patients with acquired thrombotic thrombocytopenic purpura. Blood
125:1526–1531, 2015.